Partners

People are different and so is their cancer, patients should be treated individually.

ADAPT

  • Development of an automated system for handling and deposition of tumoroids.
  • ADAPT is a joint project conducted in collaboration with engineers at the Hahn-Schickard Institute for Microanalysis Systems and the Department of Microsystems Engineering (IMTEK) at the University of Freiburg. The project is financed by a 1.000.000 EUR grant from the “Alternative Methods to Animal Testing” initiative of the German Federal Ministry of Education and Research. 2cureX will receive 110.500 EUR to validate the novel technology and integrate it into the IndiTreat® test.
  • The funds enable the development of a device for in vitro experiments with tumoroids from human tissue that meets the requirements for personalized medicine in terms of miniaturization, standardization, automation, flexibility and throughput.
  • Automation of tumoroid handling will increase the applicability of functional testing in clinical practice and improve the precision of the IndiTreat® test. This will ensure constant operator-independent quality standards across different hospitals where IndiTreat® is being implemented.
  • ADAPT started in April 2020 and will run for 36 month.

Project Details

Acronym:
ADAPT

Grant agreement ID:
031L0235C

Duration:
36 months

Start date:
1 April 2020

Topic:
Alternative Methods to Animal Testing

Funding:
110.500 EUR

Upcoming events

September 15, 2021 at 15:00 (CET)

Interview with CEO Fernando Andreu (organized by Mangold) Open participation. Details provided later.

Read more

September 23, 2021

CSO Ole Thastrup will speak at the conference “Week of Health and Innovation 2021” in Odense, Denmark

Read more and Register

September 28, 2021

Redeye Medtech & Diagnostics Investor meeting

Read more

September 29, 2021

Mangold Investor Lunch

Read more

IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.